Tryptophan hydroxylase (TPH) catalyzes the initial and rate-limiting step in the biosynthesis of serotonin, which is associated with a variety of disorders such as depression and irritable bowel syndrome. TPH exists in two isoforms; TPH1 and TPH2. TPH1 catalyzes the initial step in the synthesis of serotonin in the peripheral tissues, while TPH2 catalyzes this step in the brain. In this study, the steady-state kinetic mechanism for the catalytic domain of human TPH1 has been determined. Varying substrate tryptophan (Trp) and tetrahydrobiopterin (BH4) results in a hybrid Ping Pong-ordered mechanism in which the reaction can either occur through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan. The catalytic domain of TPH1 shares a sequence identity of 81 % with TPH2. Despite the high sequence identity, differences in the kinetic parameters of the isoforms have been identified, i.e. only TPH1 displays substrate tryptophan inhibition. This study demonstrates that the difference can be traced to an active site loop which displays different properties in the TPH isoforms. Steady-state kinetic results of the isoforms, and variants with point mutations in a loop lining the active site, show that the kinetic parameters of only TPH1 are significantly changed upon mutations. Mutations in the active site loop of TPH1 result in an increase in the substrate inhibition constant, Ki, and therefore turnover rate. Molecular dynamics simulations reveal that this substrate inhibition mechanism occurs through a closure of the co-substrate, BH4, binding pocket, which is induced by Trp binding.
Introduction
Tryptophan hydroxylase (TPH) catalyzes the first and rate-limiting reaction in the biosynthesis of the hormone and neurotransmitter serotonin . TPH uses Fe 2+ , tetrahydrobiopterin (BH4), and O2 to generate 5-hydroxytryptophan (5-HTP) by hydroxylation of tryptophan (Trp). 1 5-HTP is converted to 5-HT by aromatic amino acid decarboxylase 2, 3 . Together with phenylalanine hydroxylase (PAH) and tyrosine hydroxylase (TH), TPH is a member of the enzyme subfamily of iron(II)-containing monooxygenases which are known as aromatic amino acid hydroxylases (AAAHs). The enzymes in the AAAH family form tetramers, in which each monomeric subunit consists of an N-terminal regulatory domain, a highly conserved catalytic domain, and a C-terminal tetramerization domain. 1, 4 In human two isoforms of TPH exist, where isoform 1 (TPH1) mainly is responsible for catalyzing the initial step in the biosynthesis of peripheral serotonin, and isoform 2 (TPH2) is associated with biosynthesis of neuronal serotonin 1 . Dysregulation of serotonin levels is involved in various physiological and psychiatric disorders such as irritable bowel syndrome, depression, obsessive compulsive disorder, and schizophrenia 5 . Decreased levels of neuronal serotonin are associated with neurological disorders, whereas some gastrointestinal disorders are associated with increased peripheral serotonin levels [6] [7] [8] .
The kinetic mechanism has not unambiguously been determined for the aromatic amino acid hydroxylases.
Despite great efforts to dissect the mechanism, ambiguities still exist. Of the AAAHs, PAH and TH have been more thoroughly studied. Steady-state kinetic studies have shown that bovine TH follows a Ping Pong mechanism. 9,10 This mechanism is supported by observation that in rat TH, where oxidation of BH4 can occur in the absence of substrate tyrosine at pH 8.2. 11 However, the oxidation occurs at slower rates at pH 7.2 and not at all at pH 6.5. 11, 12 In contrast, another steady-state kinetic study on rat TH finds an ordered sequential mechanism involving a quaternary complex with all three substrates bound. 12 The presence of a ternary complex which binds O2 during catalysis in rat TH, is supported by a spectroscopic study. 13 Furthermore, a sequential mechanism is supported by single turn-over kinetic studies on PAH from chromabacterium violaceum 14 , 15 and rat 16 . Similar results have been obtained for rabbit TPH1. 17 The substrate binding order in the AAAHs have been established to occur in an ordered fashion where pterin binds followed by substrate amino acid and then O2. 9, 15, 16 That pterin binds as the first substrate is consistent with finding in TPH1 where inhibitors display uncompetitive inhibition towards 6-MePH4, which indicates that pterin binds first. 18 Additionally, the crystal structure of chicken TPH (pdb: 3E2T) shows that binding of tryptophan and possibly imidazole results in a closed conformation, which indicates the formation of a deadend complex. 19 Despite a sequence identity of 71 %, the two isoforms of TPH display differences in their kinetic properties. 20, 21 Some of the differences are accounted for by the N-terminal regulatory domains.
TPH2 has an additional 46 residues in the regulatory domain compared to TPH1. This terminal extension has a great impact on enzymatic activity, and serine 19 in the terminus of TPH2 has been identified as a phosphorylation site. 22 However, even in the absence of the regulatory domains, the isoforms display different kinetic properties. 21 Besides differences in kinetic parameters (Km and Vmax-values), TPH1 displays a greater degree of substrate tryptophan inhibition compared to TPH2. 20, 21 Human TPH1 variants without the regulatory or tetramerization domain exhibit substrate inhibition comparable to full-length TPH1. 23 The underlying molecular mechanism of this inhibition and the differences in the isoforms that govern these observations remains elusive.
Here, we describe results that identify the steady-state kinetic mechanism for the catalytic domain of human TPH1. Furthermore, we describe results that identify the structural origin of the competitive substrate inhibition mechanism. The inhibition mechanism of TPH1 is governed by the orientation of Tyr125 which enables the active site loop to participate in the mechanism. Participation of Tyr125 occurs through the adjacent Tyr235 which is found to block the active site access upon substrate Trp binding.
Experimental Procedures
Materials. All used chemicals were of analytical grade, and all solutions were prepared using water from an Dextrin Sepharose High Performance media. During purifications, all TPH containing solutions were kept in ice water, except during the chromatographic steps, which were performed at room temperature. Protein solutions were concentrated using an Amicon ultrafiltration cell with an Ultracell PL-3 membrane. Protein concentrations were determined by measuring the absorbance at 280 nm on an ND-1000 NanoDrop Spectrophotometer from Saveen Werner.
Cloning and Expression.
Full-length human TPH2 cDNA optimized for expression in E. coli was obtained from GenScript. The construct encoding the different protein variants was obtained by PCR. All DNA sequences were verified by sequencing (Eurofins). All proteins were expressed as maltose binding protein fusion proteins from the pET26 expression vector in E. coli BL21(DE3) (Novagen) cells. All TPH1 and TPH2 variants were expressed as NΔ99/CΔ31 and NΔ145/CΔ31, respectively, lacking the N-terminal regulatory domain and the C-terminal tetramerization domain. The sequences of the proteins expressed are given in Supporting Information. The recombinant fusion proteins contain a cleavage recognition site for human rhinovirus 3C protease (3CP) 24 . Proteins were expressed at 20°C for 14 h as previously described 25 .
MBP-3CP was cloned, expressed, and purified in-house.
Purification. The purification procedure comprises an affinity chromatography step utilizing a column packed with dextrin sepharose and a size exclusion step using a HiLoad Superdex 200 prep grade column, as previously described 26 . All variants were cleaved from the MBP fusion protein utilizing an on-column cleavage procedure with MBP-3CP during the first purification step. Human TPH1 variants were purified in buffer containing 20 mM TRIS/H2SO4, 100 mM (NH4)2SO4, pH 8.0 and human TPH2 variants in 20 mM HEPES/NH4OH, 100 mM (NH4)2SO4, pH 7.0. Activity Assay. The activity assay was performed as described by Moran et al. 27 and Nielsen et al. 25 , and the sample preparation was conducted as previously described 26 . The activity measurements were performed using a Varian Cary Eclipse Fluorescence Spectrophotometer. For activity measurements, the TPH variants were thawed under running water, filtered, and the concentrations were determined by UV-Vis absorption at 280 nm. The TPH samples were diluted with the buffer in which they were purified. TPH activity was assayed in a reaction mixture (10x10 mm QS quartz cuvette from Hellma -2500 µL total volume) containing achieved by equilibrating the solution with a mixture of O2 and N2 as previously described. 25 Excitation and emission wavelengths were 300 and 330 nm, respectively. Initial velocity was determined from linear regression through the first 0.04 min after BH4 addition. Apparent kinetic parameters were calculated by curve fitting using non-linear least-squares approach. When only one substrate was varied, the initial velocity data were fitted using eq. 1 or eq. 2 in case of substrate inhibition. When two substrates were varied, the initial velocity data were fitted using eq. 3. 28 35 . The MD simulations were performed with the Desmond package using the OPLS3 force-field 36 , and periodic boundary conditions in all three Cartesian coordinates were applied. Particle-mesh Ewald method 37 was applied to calculate long-range electrostatic interactions. Short-range electrostatic and van der Waals interactions were smoothly truncated at 9 Å. The simulations were run with constant number of atoms, with constant temperature of 300 K maintained with Nosé-Hoover thermostats 38 , and constant pressure maintained at 1.01325 bar with the Martyna-Tobias-Klein barostat method 39 . RESPA integrator 40 , with a 2.0-fs time step was utilized to solve the equations of motion for bonded and short-range interactions.
The RESPA integrator default setting for nonbonded interactions beyond the 0.9-nm cutoff was 6.0-fs time step. Before every 100-ns production simulation run, a relaxation with the default parameters in Desmond was performed. Configurations and energies were saved at 5-ps intervals. Convergences of the MD simulations were based on RMSD calculations.
Results
Enzymatic -Mechanism -To explore the kinetic mechanism of TPH1, the initial velocities of the catalytic domain of human TPH1 (chTPH1) was determined at various tryptophan and BH4 concentrations. The concentrations of the substrates were varied in a concentration matrix of 14 tryptophan concentrations and six BH4 concentrations. The O2 concentration was 500 µM in all measurements and apparent kinetic parameters were hence derived. This data is presented in Figure 1 . For clarity, only the lowest seven concentrations of tryptophan are shown in Figure 1B . (For all concentrations see Supporting Information Figure S1 ). Figure 1A shows that the data deviate from the classical hyperbolic curve. The data can be fitted very well with the Michaelis-Menten equation with a substrate inhibition term (eq. 2) (see Figure S2 ), which describes linear substrate inhibition resulting from a dead-end complex formation between substrate and a non-productive enzyme form. 41 When the data in Figure 1A are replotted as v0 versus [BH4], the plots in Figure 1B are obtained. The data follow a classic hyperbolic shape, and the Michaelis-Menten equation (eq. 1) fits well to the data ( Figure S3 ). By fitting eq. 2 to the data for each fixed BH4 concentration, apparent tryptophan substrate inhibition constants, Ki, can be determined. The secondary plot in Figure 2 shows that chTPH1 displays BH4 concentration-dependent substrate inhibition. For instance, at low fixed concentrations of BH4 (20 µM), chTPH1 has an apparent Ki of 24 µM, while at high BH4 concentration (400 µM) the apparent Ki is increased to 206 µM. To evaluate which mechanism the kinetic data represents, global fitting was conducted. The datasets were fitted to the velocity equations describing a i) Ping Pong mechanism with a dead-end EB complex formation, ii) sequential mechanism with a dead-end EB complex formation, iii) sequential mechanism with dead-end EA2 complex formation, and iv) hybrid Ping Pong-ordered mechanism with dead-end EB complex formation (hybrid EB). 42 The hybrid Ping Pong-ordered mechanism in Figure 3 was included in the analysis because both Ping Pong and sequential mechanisms have been observed in steady-state kinetic studies of the AAAHs. 9, 10, 12 In the hybrid model 28, 29 , the reaction can either occur through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan. Substrate inhibition is caused by competitive formation of a dead-end EB (TPH•Trp) complex formed when tryptophan binds before BH4. Such hybrid mechanisms have also been observed in e.g. pyruvate carboxylase, glutathione reductase, hypoxanthine phosphoribosyltransferase, and glutathione S-transferase A. 30, [43] [44] [45] In the global fit, the sequential mechanisms (ii and iii) resulted in identical fits, as KA was reduced to zero resulting in a reduction of the equations to that of a Ping Pong mechanism (i). For this reason, identical kinetic parameters were obtained for the three mechanisms, and the sequential mechanisms were discarded. Based on this analysis of the conventional non-branched mechanisms, a Ping Pong mechanism fit the total dataset best.
The hybrid EB model, however, results in an improved global fit (p < 0.01) compared to that of a Ping Pong mechanism, Table 1 . Fitting this model to the data results in a redundancy of K4. In the proposed hybrid mechanism in Figure 3 , the order of pterin and substrate binding is in agreement with the majority of studies conducted on the AAAHs. [9] [10] [11] [15] [16] [17] Substrate inhibition occurs through competitive inhibition by tryptophan versus BH4. This yields a BH4 concentration-dependent substrate tryptophan inhibition constant which has similarly been observed for TH 10 . A hybrid Ping Pong-ordered model in which tryptophan binds before BH4 also resulted in an improved global fit (p < 0.01) compared to that of a Ping Pong EB mechanism. This model was, however, discarded because of the accumulated experimental data, that evidently find that BH4
binds as the first substrate. [9] [10] [11] [15] [16] [17] Biphasic data was obtained by Oka et al. 10 who therefore analyzed the data separately for velocity data obtained at respectively higher or lower than 0.2 mM BH4. Such data might be explained by a hybrid Ping Pong-ordered model, which follows different mechanisms depending on substrate concentration. According to this proposed hybrid model, the reaction will occur through a sequential mechanism at high tryptophan concentrations. This correlates well with the fact that several of the AAAH studies which obtain a sequential mechanism were conducted with relatively high substrate concentrations (typically >0.5 mM range). 13, 14, 16, 17 Sequence and Structural Analysis of Isoform Differences -The human TPH isoforms display significantly different kinetic parameters, and only TPH1 is subjected to substrate inhibition. 21 In this study, it was 19 From Figure 5 , it is noticed that the side chain of the tyrosine residue is oriented towards the active site in TPH1 but is pointing away from the active site in TPH2. The structures of the loops and the orientation of the tyrosine residues in the crystal structures are assessed by electron density in the loops. The 2Fo-Fc electron density maps of the crystal structures show that the structures of the loops in both isoforms are well resolved (Supporting Information Figure S5 and S6). The Effect of Tyr125/171 Point Mutations on TPH Kinetics -In order to probe the importance of the loop in TPH, Tyr125 in chTPH1 and Tyr171 in chTPH2 were mutated to the smaller amino acid alanine or the more bulky amino acid tryptophan and characterized for changes. As the oligomeric state and the transition temperatures of the isoform mutant variants were not changed (Supporting Information, Figure S7 , Table S1 , and Figure 6 panel A and C open circles). Additionally, chTPH1 displays a 10-fold higher Km,BH4 compared to chTPH2.
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The kinetic analysis shows that mutation of the tyrosine residue in the loop results in significant changes in the kinetic parameters of chTPH1 ( Table 2 and Figure 6 ). Mutation to alanine results in a small reduction of Km,BH4, while mutation to tryptophan results in a 5-fold reduction. A change in Km,Trp is only observed for Y125W-chTPH1. Notably, the mutations result in a significant increase in the substrate inhibition constant,
Ki. Mutation to alanine increases the Ki-value slightly, while mutation to tryptophan results in a greater than 3-fold increase. The decreased substrate inhibition is clearly visualized in Figure 6 
Loop-Swap Mutations of Non-Conserved
Residues -Of the 21 residues located in the loop, only three residues are not conserved between the isoforms (Figure 4 ). To examine whether these residues contribute to the different orientations of the tyrosine residue, the three non-conserved residues in chTPH1 were mutated to the corresponding residues of the sequence of chTPH2 and vice versa. In chTPH1, His117, Ala119, and Asn120 were mutated to Lys, Ser, and His, respectively (referred to as loop-swap-chTPH1), while the opposite mutations were performed in position 163, 165, and 166 of chTPH2 (referred to as loop-swap-chTPH2). The kinetic results of the loop-swap mutations are presented in Figure 6 , and the kinetic parameters are summarized in Table Figure S8 ) with sequences of TPH1 and TPH2 from 61 and 63 vertebrate species, respectively. It was found that His117, Ala119 and Asn120 of TPH1 are 13, 100, and 97 % conserved, respectively. In TPH2, Lys163, Ser165, and His166 are conserved 75, 100, and 33 %, respectively. Of the residues in TPH1, Ala119 and Asn120 show a high degree of conservation, while for TPH2, Ser165 is highly conserved. This implies that these residues are important for proper loop orientation and function. Molecular Dynamics (MD) Simulations -MD simulations were employed to investigate the underlying mechanism that governs the observed substrate inhibition in TPH1. 100 ns MD simulations of chTPH1 with and without substrate Trp were conducted. From comparison of the trajectories, it is observed that in the presence of Trp, the entrance to the BH4 binding pocket becomes blocked, Figure 7 . The blocking of the entrance is caused mainly by Tyr235. Tyr235 is in direct contact with the active site loop through Tyr125, which is under investigation, Figure 8A . 46 
Y171W-chTPH2
Loop-swap-chTPH1
Loop-swap-chTPH2 crystal structures. The importance of Tyr235 for the inhibition mechanism of TPH1 is supported by a mutational study, in which it was found that substrate inhibition was removed upon mutation of Tyr235 to alanine or leucine. 52 In chTPH1, Tyr235 constitutes part of the BH4 binding pocket and is in direct contact with the pterin. 46 Tyr125 which is under investigation in this study, π-stacks onto Tyr235 forming a T-shaped interaction. 46 It is therefore reasonable to believe that mutation of Tyr125 has an influence on the orientation of Tyr235 and thereby explain the influence on the kinetic parameters, especially the substrate inhibition. 
Discussion
The data presented here shed light on the kinetic mechanism of TPH1 and on the different kinetic properties which are displayed by the TPH isoforms. The kinetic mechanism of TPH has not previously been determined and both Ping Pong and sequential mechanisms have been observed in steady-state kinetic studies of the AAAHs. [9] [10] [11] In this study, a hybrid Ping Pong-ordered mechanism in which the reaction can either occur through a Ping Pong or a sequential mechanism depending on the concentration of tryptophan is observed. The substrate binding order is BH4 followed by tryptophan and substrate inhibition occurs through competitive inhibition of tryptophan versus BH4. This order of substrate binding is in agreement with the majority of studies conducted on the AAAHs. [9] [10] [11] [12] [15] [16] [17] 20, 55 . Substrate inhibition is an important regulatory mechanism observed in a variety of enzymes. 56 Amino acid substrate inhibition has been observed in both full-length human TPH1
and rat TH. 57, 58 Deletion mutagenesis has shown that substrate inhibition is retained to upon deletion of either the regulatory or tetramerization domain of TPH and TH. 23, 58 This suggests that the observed substrate inhibition in full-length TPH and TH only involves the catalytic domain, which implies that the results obtained in this study can be applied to the full-length enzyme. The sequence and structural analyses of the 49, 50 A closed conformation has also been observed for chicken TPH1 with bound tryptophan and imidazole. 19 Imidazole is bound in the BH4 binding pocket, which might mimic binding of co-substrate.
However, a structure of TPH or PAH with only a substrate/substrate analogue has not been determined, and it is therefore unknown whether the loop closure occurs solely upon binding of substrate or a combination of substrate and co-substrate. The role of the loop closing mechanism is poorly understood. For PAH, it has been suggested that the closing mechanism might protect the co-substrate to enable a high degree of coupling efficiency. 59 Similarly, the loop in TH has been proposed to exclude water from the active site to avoid reaction of the water with the hydroxylating intermediate before hydroxylation of substrate can occur. 48, 60, 61 A similar functional importance of the loop in TPH is supported by the very high sequence conservation among vertebrate species observed for both TPH isoforms. From the MD simulations, it is observed that Trp binding in chTPH1 results in a blocking of the BH4 binding pocket. The Trp-induced blocking mechanism occurs through Tyr235 which moves from a BH4 binding position to a position in the opening of the BH4 binding pocket. This observation compliments the kinetic model in which a dead-end complex is formed when Trp binds before BH4. The influence of Tyr235 on the substrate inhibition mechanism is also supported by the results of Jiang et al. where mutations of Tyr235 to alanine or leucine were found to remove substrate inhibition. 52 Tyr235 is in direct contact with the active site loop through Tyr125. 46 The mutations of Tyr125 will therefore most likely have an influence on the orientation of Tyr235, and thereby explain the influence on the kinetic parameters, especially the substrate inhibition. These results strongly suggest that the inhibition mechanism, which is only observed for chTPH1, can be traced to the loop lining the active site.
The induced substrate inhibition observed in loop-swap-chTPH2 suggests that the three mutations change the orientation of the loop to an orientation approaching the one observed in chTPH1.
Besides chTPH1, substrate inhibition is also observed in TH. For TH, substrate inhibition is observed at tyrosine concentrations higher than 50 µM 62 . The tyrosine concentration in the brain has been found to vary as much as a factor of two. 63 Substrate inhibition of TH has been proposed to explain the lack of L-DOPA concentration fluctuations as a consequence of increase Tyr concentration upon food intake. 56 Trp concentrations are around 60 µM in the blood 64 which is close to the Trp concentration at which the maximum velocity of TPH1 is achieved in this study. This suggests that substrate inhibition could play a role in the TPH1 regulation in vivo. It is possible that a corresponding mechanism observed for TH is ensuring that the production of 5-HT does not rise to high levels in the peripheral tissues, which is associated with several diseases. 65 The concentration of tryptophan in the brain is in the range of 25-35 µM 66 which is close to the observed Km,Trp of chTPH2. The velocities of 5-HTP production and in turn serotonin production are, therefore, very sensitive to changes in brain Trp concentration. 66, 67 This might explain the lack of substrate inhibition observed in TPH2, as rapid responses are desirable in the brain. It could be speculated that different regulatory mechanisms of the two isoforms have evolved to accommodate the diverse need for serotonin biosynthesis in different tissues.
Associated content
Supporting information
Sequences of hTPH2 protein variants and MBP-3CP. Steady-state kinetic results ( Figure S1-S3 ). Structural analysis of TPH isoform sequence conservation ( Figure S4 ). TPH1 and TPH2 loop densities ( Figure S5 and S6). Experimental procedure and results obtained from analytical gel filtration of the TPH variants ( Figure   S7 and Table S1 ). Experimental procedure and results obtained from differential scanning fluorimetry measurements conducted on TPH variants (Table S2 ). Logo conservation plots of the active site loops of the TPH isoforms ( Figure S8 ).
